AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01073930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PicoPrep
Description: PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
Study NCT01073930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HalfLytely
Description: HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
Study NCT01073930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisacodyl
Description: Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
Study NCT02327988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Study NCT02327988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Study NCT01609998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza DNA vaccine
Description: VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
Study NCT01609998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study NCT01609998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study NCT04934644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Description: Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
Study NCT01209078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: GSK1322322 1500mg BID
Study NCT01209078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600mg
Study NCT01209078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1322322 placebo
Description: Placebo
Study NCT01209078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid placebo
Description: placebo
Study NCT02699203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal
Description: Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
Study NCT02639104 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates
Study NCT02639104 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiography
Description: Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates
Study NCT02639104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms.
Study NCT02639104 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electromyography
Description: Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms.
Study NCT02331225 — intervention group
Intervention type: OTHER
Intervention: No intervention given
Description: There is no intervention for this study
Study NCT03121092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI or ARB
Description: Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
Study NCT02504697 — intervention group
Intervention type: OTHER
Intervention: Biosamples from airway and blood
Description: Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Study NCT03970369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Personalized goals and an activity prescription.
Study NCT03970369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Personalized goals and an activity prescription.
Study NCT03970369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor
Description: Participants wear a step counter to track activity goals.
Study NCT03291652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DSA/3DRA
Description: DSA/3DRA
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Study NCT02356783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pedometer
Description: Wireless pedometer
Study NCT01853046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
Study NCT01948817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox 20mg/kg taken BID
Study NCT02355691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVENA
Description: The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
Study NCT04479956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varicose vein surgery
Description: sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
Study NCT03210870 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nutritional education classes
Description: The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
Study NCT04430777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Administration of tranexamic acid 1 gr either intravenously or subcutaneously
Study NCT04430777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: Administration of tranexamic acid 1 gr either intravenously or subcutaneously
Study NCT01940809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT01940809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01940809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04005924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinogalactan
Description: Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
Study NCT00930319 — intervention group
Intervention type: OTHER
Intervention: Firmagon given by prescription according to SPC
Description: Non-interventional,observational Firmagon given by prescription according to SPC
Study NCT01434732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
Study NCT03103464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Therapy + Sit-to-Stand Therapy
Description: Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
Study NCT03103464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Therapy
Description: Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
Study NCT01375491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: generic doxycycline 100mg twice daily
Study NCT01375491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to doxycycline
Study NCT04415931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL
Study NCT04415931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Standard interscalene brachial plexus regional block
Study NCT03472339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
Study NCT03472339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
Study NCT01310491 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Health coaching
Description: Telephone based health coaching supported by tele-monitoring.
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomepromazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioridazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melperone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pipamperone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromperidol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benperidol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorprothixene
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluspirilene
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiapride
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothipendyl
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study NCT01434732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Cord Clamping
Description: The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
Study NCT02358304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray calcitonin
Description: recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
Study NCT02358304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01269307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 ketamine-propofol mixture sedation
Description: Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine
Study NCT01269307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Sedation
Description: Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temazepam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brotizolam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaleplon
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomethiazole
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomipramine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opipramol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimipramine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maprotiline
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline oxide
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moclobemide
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mianserin
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine